AstraZeneca PLCAZN:LSE

33.50 / 0.71%
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jan 26 2015 16:40 GMT.

Income statement in USD

Year on year AstraZeneca PLC's revenues fell 8.09% from 27.97bn to 25.71bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 6.24bn to 2.56bn, a 59.04% decrease. View full income statement

Gross margin79.53%
Net profit margin3.95%
Operating margin7.22%
Return on assets1.88%
Return on equity4.71%
Return on investment2.60%

Growth rates in USD

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by 58.71%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.

Div yield(5 year avg)0.09%
Div growth rate (5 year)6.43%
Payout ratio (TTM)231.94%
EPS growth(5 years)-13.4583
EPS (TTM) vs
TTM 1 year ago

Cash flow in USD

In 2013, AstraZeneca PLC increased its cash reserves by 18.42%, or 1.40bn. The company earned 7.40bn from its operations for a Cash Flow Margin of 28.78%. In addition the company used 2.89bn on investing activities and also paid 3.05bn in financing cash flows. View full cash flow statement

Cash flow per share3.12
Price/Cash flow per share15.20
Book value per share10.79
Tangible book value per share-5.9489

Balance sheet in USD

AstraZeneca PLC has a Debt to Total Capital ratio of 32.66%, a lower figure than the previous year's 36.85%. View full balance sheet

Current ratio0.9525
Quick ratio0.8288
Total debt/total equity0.4855
Total debt/total capital0.3266
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.